RA06.08: PATIENTS WITH FUNCTIONAL REFLUX SYMPTOMS DO NOT DIFFER SUBJECTIVELY FROM PATIENTS WITH GERD

2018 ◽  
Vol 31 (Supplement_1) ◽  
pp. 32-33
Author(s):  
Sedat Ciftci ◽  
Michael Weitzendorfer ◽  
Dariya Kalcheva ◽  
Lisa Manzenreiter ◽  
Klaus Emmanuel ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Gastroesophageal Reflux Disease ◽  
Gastroesophageal Reflux ◽  
Impedance Measurement ◽  
Demeester Score ◽  
Reflux Symptoms ◽  
Significant Difference ◽  
Functional Complaints ◽  
Ph Metry

Abstract Background Patients with gastroesophageal reflux disease (GERD) often suffer greatly from their symptoms. The aim of this study was to determine if there is a difference in quality of life and gastrointestinal symptom complexes between patients with purely functional complaints and patients with objective GERD Methods Included were all patients with typical reflux symptoms who had GERD examination in 2017 at our department. All patients underwent high resolution manometry, 24-h ph-metry impedance measurement and gastroscopy. Quality of life was assessed using the Gastrointestinal Quality of Life Index (GIQLI) and gastrointestinal symptoms using a Symptom Checklist (SCL) assessing the severity and intensity of 14 different symptoms. Based on the results of the 24-h ph-metry impedance measurement, patients were divided into 2 groups. Patients with functional reflux symptoms and patients with GERD. These two groups were compared. Results Complete data was available in 162 patients, of whom 86 patients (52.2%) were objectively reflux sick (DeMeester score mean: 37.85, SD ± 29.11) and 76 patients (46.1%) had a normal DeMeester score (Mean: 7.01, SD ± 4.09). Between the two groups no significant difference in quality of life was found (mean GIQLI of GERD patients: 94.81, SD ± 22.40, and mean GIQLI of patients with functional reflux symptoms: 95.26, SD ± 20.33, P = 0.988).Furthermore no significant difference could be found in symptoms (mean general SCL score of reflux patients:46.97, SD ± 29.23, of patients with functional reflux symptoms: 48.03, SD ± 29.17, P = 0.827). Conclusion Patients with functional complaints suffer just as much from their symptoms as patients who are objectively reflux sick. A differentiation between gastroesophageal reflux disease and functional reflux symptoms is only possible by means of functional diagnostics. Disclosure All authors have declared no conflicts of interest.

scholarly journals Evaluation of the Additive Effect of Domperidone on Patients with Refractory Gastroesophageal Reflux Disease; A Randomized Double Blind Clinical Trial

2018 ◽  
Vol 11 (1) ◽  
pp. 24-31 ◽  
Author(s):  
Tarang Taghvaei ◽  
Arash Kazemi ◽  
Vahid Hosseini ◽  
Mehdi Hamidian ◽  
Hafez Tirgar Fakheri ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Trial ◽  
Gastroesophageal Reflux Disease ◽  
Gastroesophageal Reflux ◽  
Erosive Esophagitis ◽  
Double Blind ◽  
Double Blind Clinical Trial ◽  
Significant Difference ◽  
Before And After

BACKGROUND Gastroesophageal reflux disease (GERD) is a common problem with annoying symptoms. It is associated with negative impact on quality of life. Prokinetic agents may be used in combination with acid suppression agents as an adjunctive in patients with GERD refractory to proton pump inhibitors (PPI) therapy, rather than as sole treatment. This study aimed to evaluate the efficacy of combination of PPI with domperidone (a prokinetic agent) compared with PPI alone in the treatment of patients with refractory GERD. METHODS This study was a double blind clinical trial on 29 patients with GERD refractory to PPI during the period of one month. By randomization, the patients were divided into two groups. Group A was treated by pantoprazole 40 mg twice daily and domperidone three times a day for a month, while group B was treated by pantoprazole 40 mg twice daily and placebo three times a day. In this study endoscopy was performed to evaluate the prevalence of erosive esophagitis, non-erosive reflux, and hiatal hernia. Manometry was conducted to study the prevalence of dysmotility. GERD symptom questionnaires including the Gastrointestinal Symptom Rating Scale (GSRS), Carlson Dennett, and the Medical Outcomes Study Short Form-36 health survey (SF36) were used before and after treatment for screening GERD and assessing treatment response. RESULTS There were 17 (58.62%) women and 12 (41.37%) men. The prevalence of erosive esophagitis and non-erosive reflux, was 10.34% and 89.66%, respectively. There was a significant difference comparing reflux symptoms before and after treatment between the two groups according to reflux and Carlson Dennett questionnaires. At the end of the study, symptoms of reflux significantly improved by treatment. Although, the quality of life questionnaire scores improved by treatment, there was no statistically significant difference in response to treatment between the two groups. CONCLUSION In this research, we showed that adding domperidone to PPI could not make any improvement in patients with refractory reflux regarding the quality of life and improving the symptoms.

Mucosal Protective Compounds in the Treatment of Gastroesophageal Reflux Disease. A Position Paper Based on Evidence of the Romanian Society of Neurogastroenterology

2016 ◽  
Vol 25 (4) ◽  
pp. 537-546 ◽  
Author(s):  
Teodora Surdea-Blaga ◽  
Ion Băncilă ◽  
Daniela Dobru ◽  
Vasile Drug ◽  
Ovidiu Frățilă ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Gastroesophageal Reflux Disease ◽  
Gastroesophageal Reflux ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Reflux Disease ◽  
Position Paper ◽  
Esophageal Mucosa ◽  
Reflux Symptoms

Background & Aims: Gastroesophageal reflux disease (GERD) therapy is challenging and suppression of acid secretion or prokinetics do not cure all cases. Some drugs with protective action on the esophageal mucosa have been used alternatively or in association with proton pump inhibitors (PPIs) and/or prokinetics. The Romanian Society of Neurogastroenterology undertook an Evidence-Based analysis, from which this position paper evolved. Methods: We performed a systematic literature search in PubMed until October 2015, using the terms: sucralfate, guaiazulene, gaiazulene, dimethicone, alginate, antacids and gastroesophageal reflux. Forty-seven papers were included and analyzed. Several statements were elaborated regarding the use of these drugs in GERD. The evidence and recommendations were discussed between the authors. Results: There is evidence in the medical literature suggesting the benefit of these drugs in GERD. In patients with persistent or mild reflux symptoms antacids rapidly relieve heartburn. Alginate-antacid combination is superior both over placebo and antacids to treat mild reflux symptoms, and can be used to treat persistent reflux symptoms despite acid suppressant therapy. Sucralfate is superior over placebo in alleviating GERD symptoms and can be used as maintenance therapy. Guaiazulene-dimethicone improves the quality of life in patients with GERD. Conclusions: Drugs used to protect the esophageal mucosa against acid are useful in alleviating chronic heartburn, especially in patients with mild reflux symptoms. Abbreviations: CS: Chondroitin sulfate; DA: Double Action; EE : Erosive esophagitis ; GERD: Gastroesophageal reflux disease; HA: Hyaluronic acid; H2RA: Histamine 2 receptor antagonist; ITT: Intention to treat; IM: Irsogladine maleate; NERD: Non-erosive reflux disease; PPIs: Proton pump inhibitors; RCT: Randomized controlled trial; RDQ: Reflux disease questionnaire; QoL: Quality of life.

scholarly journals The burden of gastroesophageal reflux disease on patients’ daily lives: A cross-sectional study conducted in a primary care setting in Serbia

2015 ◽  
Vol 143 (11-12) ◽  
pp. 676-680
Author(s):  
Milos Bjelovic ◽  
Tamara Babic ◽  
Igor Dragicevic ◽  
Aleksandar Corac ◽  
Goran Trajkovic
Keyword(s):  
Quality Of Life ◽  
Gastroesophageal Reflux Disease ◽  
Gastroesophageal Reflux ◽  
Reflux Disease ◽  
Activity Limitation ◽  
Health Related Quality ◽  
Reflux Symptoms ◽  
Related Quality ◽  
Health Related

Introduction. Recent data from the studies conducted in the Western countries have proved that patients with gastroesophageal reflux disease have significantly impaired health-related quality of life compared to general population. Objective. The study is aimed at evaluating the burden of reflux symptoms on patients? health-related quality of life. Methods. The study involved 1,593 patients with diagnosed gastroesophageal reflux disease. The Serbian version of a generic self-administered Centers for Disease Control and Prevention questionnaire was used. Statistical analyses included descriptive statistics, Pearson chi-square test and a multiple regression model. Results. Among all participants, 43.9% reported fair or poor health. Mean value of unhealthy days during the past 30 days was 10.4 days, physically unhealthy days 6.4 days, mentally unhealthy days 5.3 days and activity limitation days 4.3 days. Furthermore, 24.8% participants reported having ?14 unhealthy days, 14.9% had ?14 physically unhealthy days, 11.8% reported ?14 mentally unhealthy days, and 9.4% had ?14 activity limitation days. Conclusion. This study addressed complex relationships between reflux symptoms and patients? impaired everyday lives.

Quality of life in type 2 diabetics with gastroesophageal reflux disease: a case control study

2013 ◽  
Vol 45 (4) ◽  
pp. 194-199 ◽  
Author(s):  
R. Promberger ◽  
A. Spitzer ◽  
J. Ott ◽  
J. Lenglinger ◽  
W. Eilenberg ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Gastroesophageal Reflux Disease ◽  
Gastroesophageal Reflux ◽  
Reflux Disease ◽  
Case Control Study ◽  
Case Control ◽  
Type 2 Diabetics ◽  
Control Study
Sign in / Sign up

Export Citation Format

Share Document